Journal of Infection
Volume 61, Issue 2 , Pages 189-190 , August 2010

Severe acute renal failure associated with rhabdomyolysis during treatment with raltegravir. A call for caution

  • Félix Gutiérrez

      Affiliations

    • Corresponding Author InformationCorresponding author. Unidad de Enfermedades Infecciosas, Hospital General Universitario de Elche, Camí de la Almazara 11, 03203 Elche, Spain. Tel.: +34 96 667 91 54; fax: +34 96 667 91 56.

,Accepted 29 April 2010.

References 

  1. Hughes A, Barber T, Nelson M. New treatment options for HIV salvage patients: an overview of second generation PIs, NNRTIs, integrase inhibitors and CCR5 antagonists. J Infect. 2008;57:1–10
  2. U.S. Food and Drug Administration . Raltegravir label information. (updated November 04, 2009) http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory#apphist
  3. Hicks C, Gulick RM. Raltegravir: the first HIV type 1 integrase inhibitor. Clin Infect Dis. 2009;48:931–939
  4. Connelly S. Raltegravir NDA 22–145. U.S. Food and Drug administration division of antiviral products antiviral drugs advisory committee meeting; September 5, 2007. http://www.fda.gov/OHRMS/DOCKETS/AC/07/slides/2007-4314s1-06-connelly.ppt#256,1,Raltegravir
  5. Zembower TR, Gerzenshtein L, Coleman K, Palella FJ. Severe rhabdomyolysis associated with raltegravir use. AIDS. 2008;22:1382–1384
  6. Dori L, Buonomini AR, Viscione M, Sarmati L, Andreoni M. A case of rhabdomiolysis associated with raltegravir use. AIDS. 2010;24:473–475

PII: S0163-4453(10)00131-3

doi: 10.1016/j.jinf.2010.04.011

Journal of Infection
Volume 61, Issue 2 , Pages 189-190 , August 2010

Article Tools